Highlights
- •Lipoprotein levels in ALS results showing low IDL-B and high LDL-1 concentrations.
- •No association between lipoprotein or apolipoprotein levels and clinical findings.
- •There was no difference in the LDL/HDL ratio no association with disease evolution.
Abstract
Introduction
Converging evidence highlights that lipid metabolism plays a key role in ALS pathophysiology.
Dyslipidemia has been described in ALS patients and may be protective but peripheral
lipoprotein subclasses have never been studied.
Material and methods
We collected sera from 30 ALS patients and 30 gender and age-matched controls. We
analyzed 11 distinct lipoprotein subclasses by linear polyacrylamide gel electrophoresis
(Lipoprint, Quantimetrix Corporation, USA). We also measured lipoprotein (a), apolipoprotein
B, and apolipoprotein E levels.
Results
ALS patients had significant higher total cholesterol, HDL-cholesterol, and LDL-cholesterol
levels than controls (p < 0.0001, p = 0.0007, and p = 0.0065, respectively). The LDL-1 subfraction concentration was higher (1.03 ± 0.41 vs. 0.71 ± 0.28 mmol/L; p = 0.0006) and the IDL-B subfraction lower (6.5 ± 2% vs. 8.0 ± 2%; p = 0.001) in ALS patients than controls.
Discussion
Our preliminary work confirmed the association between ALS and dyslipidemia. The low
IDL-B levels may explain the hepatic steatosis frequently reported in ALS. The high
levels of the cholesterol-rich LDL-1 subfraction is consistent with previously reported
hypercholesterolemia.
Conclusion
This study describes, for the first time, the distribution of serum lipoproteins in
ALS patients, with low IDL-B and high LDL-1 subfraction level.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Energy metabolism in amyotrophic lateral sclerosis.Lancet Neurol. 2011; 10: 75-82
- Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.Am. J. Clin. Nutr. 2001; 74: 328-334
- High metabolic level in patients with familial amyotrophic lateral sclerosis.Amyotroph. Lateral Scler. 2009; 10: 113-117
- Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.Neurodegener. Dis. 2005; 2: 202-207
- Management of ALS: nutritional care.Neurology. 1996; 47: S118-120
- Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis.J. Lipid Res. 2007; 48: 1571-1580
- Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.Neurology. 2008; 70: 1004-1009
- Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study.Intern. Med. 2012; 51: 1501-1508
- Lower serum lipid levels are related to respiratory impairment in patients with ALS.Neurology. 2009; 73: 1681-1685
- Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?.J. Clin. Neurol. 2013; 9: 125-129
- Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice.PLoS One. 2011; 6: e17985
- Lower serum lipid levels are related to respiratory impairment in patients with ALS.Neurology. 2010; 74 (author reply 2027–2028): 2027
- Abnormalities of lipoprotein and carbohydrate metabolism in degenerative diseases of the nervous system—motor neuron disease and spinocerebellar degeneration.Tohoku J. Exp. Med. 1983; 139: 365-376
- Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis?.Neurol. Res. 2012; 34: 576-580
- Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.Muscle Nerve. 2011; 44: 20-24
- The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis.Amyotroph. Lateral Scler. Frontotemporal Degener. 2015; 16: 359-365
- Dyslipidemia in ALS: good, bad, or unclear?.Neurology. 2008; 70: 988-989
- Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.Lancet. 2014; 383: 2065-2072
- Serum low density lipoprotein subclasses in asthma.Respir. Med. 2013; 107: 1866-1872
- “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.Curr. Vasc. Pharmacol. 2011; 9: 533-571
- Biochemical evaluation of the results of lipid regulating treatment in France.Arch. Mal. Coeur Vaiss. 2005; 98: 58-62
- Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis.Eur. J. Neurol. 2015; 22: 1385-1390
- Defective cholesterol metabolism in amyotrophic lateral sclerosis.J. Lipid Res. 2016;
- Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis.J. Neurol. Neurosurg. Psychiatry. 2011; 82: 638-642
- Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.Atherosclerosis. 1992; 93: 189-199
- Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression.Arterioscler. Thromb. Vasc. Biol. 1996; 16: 697-704
- Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.Circulation. 1997; 95: 2022-2026
- Introduction to Lipids and Lipoproteins.2000
Article info
Publication history
Published online: July 17, 2017
Accepted:
July 16,
2017
Received in revised form:
July 6,
2017
Received:
April 6,
2017
Identification
Copyright
© 2017 Elsevier B.V. All rights reserved.
